GOSSAMER BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
GOSSAMER BIO, INC. (GOSS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $1.74 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.84, a 25.17% increase year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.47, a 63.61% decline year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $4.04, a 51.56% decline year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $8.34, a 46.16% decline year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $1.79, a 20.44% decline from fiscal 2024.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $2.25, a 79.67% decline from fiscal 2023.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $11.07, a 29.45% decline from fiscal 2022.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $15.69, a 10.96% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.74 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $1.84 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $1.79 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $1.99 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $2.02 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $1.47 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $2.25 10-K · filed 2026-03-17 | |||
| 2024-09-30 | $1.85 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $1.64 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $4.04 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $11.07 10-K · filed 2026-03-17 | |||
| 2023-09-30 | $11.12 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $11.33 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $8.34 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $15.69 10-K · filed 2025-03-13 | |||
| 2022-09-30 | $15.77 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $16.50 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $15.49 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $14.14 10-K · filed 2024-03-05 | |||
| 2021-09-30 | $14.01 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $13.71 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $16.06 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $15.99 10-K · filed 2023-03-17 | |||
| 2020-09-30 | $13.61 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $12.96 10-Q · filed 2020-08-11 | |||
| 2020-03-31 | $15.50 10-Q · filed 2020-05-12 | |||
| 2019-12-31 | $11.64 10-K · filed 2022-03-03 | |||
| 2019-09-30 | $12.30 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $10.75 10-Q · filed 2019-08-08 | |||
| 2018-12-31 | $4.85 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |